Trevi Therapeutics, Inc.
TRVI
$13.35
$0.050.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -45.86M | -47.30M | -47.35M | -47.91M | -44.32M |
| Total Depreciation and Amortization | 151.00K | 149.00K | 149.00K | 147.00K | 144.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | 390.00K |
| Total Other Non-Cash Items | 3.91M | 3.35M | 3.14M | 2.68M | 2.16M |
| Change in Net Operating Assets | -2.21M | 1.11M | 2.79M | 6.83M | 6.55M |
| Cash from Operations | -44.01M | -42.68M | -41.27M | -38.26M | -35.07M |
| Capital Expenditure | -19.00K | -7.00K | -35.00K | -35.00K | -50.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -87.35M | -28.76M | -23.35M | -21.49M | 15.24M |
| Cash from Investing | -87.37M | -28.77M | -23.39M | -21.53M | 15.19M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -42.00K | -74.00K | -105.00K | -126.00K | -127.00K |
| Issuance of Common Stock | 172.32M | 176.21M | 70.54M | 61.61M | 10.15M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -84.00K | -590.00K | -222.00K | -- | -58.00K |
| Cash from Financing | 172.20M | 175.55M | 70.22M | 61.48M | 9.96M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 40.82M | 104.10M | 5.56M | 1.70M | -9.91M |